v3.26.3
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2026
Sep. 30, 2025
Sep. 30, 2026
Sep. 30, 2025
Operating expenses        
Research and development $ 12,068 $ 10,328 $ 36,457 $ 22,132
Selling, general and administrative 5,660 6,478 16,628 17,804
Total operating expenses 17,728 16,806 53,085 39,936
Net operating loss (17,728) (16,806) (53,085) (39,936)
Interest income 1,036 1,017 2,878 2,901
Other expense, net (12) (15) (16) (24)
Net loss $ (16,704) $ (15,804) $ (50,223) $ (37,059)
Net loss per share, basic $ (0.31) $ (0.4) $ (1.01) $ (0.96)
Net loss per share, diluted $ (0.31) $ (0.4) $ (1.01) $ (0.96)
Weighted average number of common shares and prefunded warrants outstanding, basic 53,452,869 39,741,404 49,880,130 38,644,395
Weighted average number of common shares and prefunded warrants outstanding, diluted 53,452,869 39,741,404 49,880,130 38,644,395